Atorvastatin-induced cardioprotection is mediated by increasing inducible nitric oxide synthase and consequent S-nitrosylation of cyclooxygenase-2 - PubMed (original) (raw)
. 2006 May;290(5):H1960-8.
doi: 10.1152/ajpheart.01137.2005. Epub 2005 Dec 9.
Affiliations
- PMID: 16339820
- DOI: 10.1152/ajpheart.01137.2005
Free article
Atorvastatin-induced cardioprotection is mediated by increasing inducible nitric oxide synthase and consequent S-nitrosylation of cyclooxygenase-2
Shaul Atar et al. Am J Physiol Heart Circ Physiol. 2006 May.
Free article
Abstract
We determined the effects of cyclooxygenase-1 (COX-1; SC-560), COX-2 (SC-58125), and inducible nitric oxide synthase (iNOS; 1400W) inhibitors on atorvastatin (ATV)-induced myocardial protection and whether iNOS mediates the ATV-induced increases in COX-2. Sprague-Dawley rats received 10 mg ATV.kg(-1).day(-1) added to drinking water or water alone for 3 days and received intravenous SC-58125, SC-560, 1400W, or vehicle alone. Anesthesia was induced with ketamine and xylazine and maintained with isoflurane. Fifteen minutes after intravenous injection rats underwent 30-min myocardial ischemia followed by 4-h reperfusion [infarct size (IS) protocol], or the hearts were explanted for biochemical analysis and immunoblotting. Left ventricular weight and area at risk (AR) were comparable among groups. ATV reduced IS to 12.7% (SD 3.1) of AR, a reduction of 64% vs. 35.1% (SD 7.6) in the sham-treated group (P < 0.001). SC-58125 and 1400W attenuated the protective effect without affecting IS in the non-ATV-treated rats. ATV increased calcium-independent NOS (iNOS) [11.9 (SD 0.8) vs. 3.9 (SD 0.1) x 1,000 counts/min; P < 0.001] and COX-2 [46.7 (SD 1.1) vs. 6.5 (SD 1.4) pg/ml of 6-keto-PGF(1alpha); P < 0.001] activity. Both SC-58125 and 1400W attenuated this increase. SC-58125 did not affect iNOS activity, whereas 1400W blocked iNOS activity. COX-2 was S-nitrosylated in ATV-treated but not sham-treated rats or rats pretreated with 1400W. COX-2 immunoprecipitated with iNOS but not with endothelial nitric oxide synthase. We conclude that ATV reduced IS by increasing the activity of iNOS and COX-2, iNOS is upstream to COX-2, and iNOS activates COX-2 by S-nitrosylation. These results are consistent with the hypothesis that preconditioning effects are mediated via PG.
Similar articles
- Enhanced cardioprotection against ischemia-reperfusion injury with combining sildenafil with low-dose atorvastatin.
Rosanio S, Ye Y, Atar S, Rahman AM, Freeberg SY, Huang MH, Uretsky BF, Birnbaum Y. Rosanio S, et al. Cardiovasc Drugs Ther. 2006 Feb;20(1):27-36. doi: 10.1007/s10557-005-5203-4. Cardiovasc Drugs Ther. 2006. PMID: 16435070 - Myocardial protection by pioglitazone, atorvastatin, and their combination: mechanisms and possible interactions.
Ye Y, Lin Y, Atar S, Huang MH, Perez-Polo JR, Uretsky BF, Birnbaum Y. Ye Y, et al. Am J Physiol Heart Circ Physiol. 2006 Sep;291(3):H1158-69. doi: 10.1152/ajpheart.00096.2006. Epub 2006 Apr 7. Am J Physiol Heart Circ Physiol. 2006. PMID: 16603698 - The role of eNOS, iNOS, and NF-kappaB in upregulation and activation of cyclooxygenase-2 and infarct size reduction by atorvastatin.
Ye Y, Martinez JD, Perez-Polo RJ, Lin Y, Uretsky BF, Birnbaum Y. Ye Y, et al. Am J Physiol Heart Circ Physiol. 2008 Jul;295(1):H343-51. doi: 10.1152/ajpheart.01350.2007. Epub 2008 May 9. Am J Physiol Heart Circ Physiol. 2008. PMID: 18469150 - Discovery of a new function of cyclooxygenase (COX)-2: COX-2 is a cardioprotective protein that alleviates ischemia/reperfusion injury and mediates the late phase of preconditioning.
Bolli R, Shinmura K, Tang XL, Kodani E, Xuan YT, Guo Y, Dawn B. Bolli R, et al. Cardiovasc Res. 2002 Aug 15;55(3):506-19. doi: 10.1016/s0008-6363(02)00414-5. Cardiovasc Res. 2002. PMID: 12160947 Free PMC article. Review. - Anesthetic modulation of immune reactions mediated by nitric oxide.
Toda N, Toda H, Hatano Y. Toda N, et al. J Anesth. 2008;22(2):155-62. doi: 10.1007/s00540-007-0590-2. Epub 2008 May 25. J Anesth. 2008. PMID: 18500613 Review.
Cited by
- Protein S-nitrosylation in health and disease: a current perspective.
Foster MW, Hess DT, Stamler JS. Foster MW, et al. Trends Mol Med. 2009 Sep;15(9):391-404. doi: 10.1016/j.molmed.2009.06.007. Epub 2009 Aug 31. Trends Mol Med. 2009. PMID: 19726230 Free PMC article. Review. - Optimization of Timing and Times for Administration of Atorvastatin-Pretreated Mesenchymal Stem Cells in a Preclinical Model of Acute Myocardial Infarction.
Xu J, Xiong YY, Li Q, Hu MJ, Huang PS, Xu JY, Tian XQ, Jin C, Liu JD, Qian L, Yang YJ. Xu J, et al. Stem Cells Transl Med. 2019 Oct;8(10):1068-1083. doi: 10.1002/sctm.19-0013. Epub 2019 Jun 27. Stem Cells Transl Med. 2019. PMID: 31245934 Free PMC article. - Total Flavonoids from Radix Glycyrrhiza Exert Anti-Inflammatory and Antitumorigenic Effects by Inactivating iNOS Signaling Pathways.
Jiang YX, Dai YY, Pan YF, Wu XM, Yang Y, Bian K, Zhang DD. Jiang YX, et al. Evid Based Complement Alternat Med. 2018 May 22;2018:6714282. doi: 10.1155/2018/6714282. eCollection 2018. Evid Based Complement Alternat Med. 2018. PMID: 29951107 Free PMC article. - Ischemic tolerance - blessing or curse.
Burda J, Burda R. Burda J, et al. Physiol Res. 2021 Nov 29;70(5):661-670. doi: 10.33549/physiolres.934644. Epub 2021 Sep 10. Physiol Res. 2021. PMID: 34505532 Free PMC article. Review. - Protective Role of Vitamin B1 in Doxorubicin-Induced Cardiotoxicity in Rats: Focus on Hemodynamic, Redox, and Apoptotic Markers in Heart.
Rankovic M, Draginic N, Jeremic J, Samanovic AM, Stojkov S, Mitrovic S, Jeremic N, Radonjic T, Srejovic I, Bolevich S, Svistunov A, Jakovljevic V, Turnic TN. Rankovic M, et al. Front Physiol. 2021 Sep 22;12:690619. doi: 10.3389/fphys.2021.690619. eCollection 2021. Front Physiol. 2021. PMID: 34630136 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials